M. Weiss

发表

Fingolimod (FTY720) in Severe Hepatic Impairment: Pharmacokinetics and Relationship to Markers of Liver Function

J. Kovarik, H. Schmidt, H. Schmidt, 2006, Journal of clinical pharmacology.

Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3.

Imad Hanna, A. Drollmann, E. Greco, 2021, Pulmonary pharmacology & therapeutics.

The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant.

B. Lambrecht, C. Brightling, D. Sandham, 2021, Pulmonary pharmacology & therapeutics.

Fevipiprant (QAW039) demonstrates safety, tolerability and consistent PK at high oral doses

V. Erpenbeck, Janardhana Vemula, Kayoko Matsumoto, 2017 .

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers

S. Neelakantham, V. Erpenbeck, M. Larbig, 2016, Clinical pharmacology in drug development.

Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

Baldur P Magnusson, T. Popov, S. Weinstein, 2016, Data in brief.

ACh receptor partial agonist: pharmacological characterization and phase I

D. Hoyer, G. Bilbe, C. Pryce, 2015 .

AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.

L. Grégoire, T. Di Paolo, B. Gomez-Mancilla, 2014, Parkinsonism & related disorders.

Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial

R. P. Maguire, D. Barch, M. Harms, 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

D. Hoyer, G. Bilbe, K. Lingenhoehl, 2015, British journal of pharmacology.

The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.

Baldur P Magnusson, Todor A Popov, S. Weinstein, 2016, Pulmonary pharmacology & therapeutics.

Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes.

A. Nica, R. Woessner, H. Tillmann, 2019, Pulmonary pharmacology & therapeutics.

A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia

L. Defebvre, I. Rozenberg, O. Rascol, 2016, Movement Disorders.

QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study

Baldur P Magnusson, Todor A Popov, S. Miller, 2015 .